Our Partners

Raj Kumar MB ChB D.P.M.

• President R & D: Ranbaxy and Dr Reddy’s Laboratories
• Glaxo Smithkline Vice President and Global Head Of Psychiatry 2000-2002
• SmithKline Beecham (1998 - 2000)
• Vice President and Medical Director
• Responsible for worldwide clinical development in Neuroscience and GI
• Over 40 employees; $30 million annual budget
• SB ( 1997-1998) Group Director and Head of Psychiatry
• SB (1995-1997) Director
• SB (1992-1995) Associate Director
• SB (1990-1992) Assistant Director
• Multinational Clinical and Regulatory experience, including Japan
• Direct clinical trial experience in psychiatry, neurology, gastroenterology and clinical pharmacology
• Recent NDAs Approved:
• Paxil $ 1.7 revenue
• Paxil Social Phobia $ 2.1 revenue
• Paxil- GAD
• Paxil -PTSD
• Paxil 1st $2 billion dollar drug for SB

Tom Blacburn, DSc., PhD BSC

• Vice President, Drug Development Operations, at Synaptic Pharmaceutical Corporation before joining Lundbeck Inc. as a Senior Director of Medical Affairs and US R&D Liaison in July 2003
• Synaptic in March 1999, as Vice President of Pharmacology
• Director for ten years in the Neuroscience Department at SmithKlineBeecham, in the U.K. During this time he worked on the pharmacology and development of selective 5-HT­2C receptor antagonists and the SSRI, paroxetine, (Seroxat, Paxil)
• He has an extensive knowledge of pharmacology and clinical drug development and has published over 90 papers in the field of neuroscience and he is an inventor on several patents
• Much of his research has been focused on serotonin (5-HT), dopamine, opioid receptor subtypes as well as potassium, 5-HT3 and GABAA ion channels drugs
• GPCR target for the treatment of depression together with the development of several other novel GPCR approaches for the treatment of CNS disorders

Ajay Kumar MB.Bchir MA (Cantab)

• University of Cambridge, Downing College 1999-2005
• MB.BChir
• MA Anatomy- Neuroscience
• Registrar in Medicine
• Anatomy Supervisor, Wolfson College, University of Cambridge
• Development Biology and Pharmacology, Hughes Hall, University of Cambridge
• Member of Institute of Directors

Rocco Zanineli PhD, MD

• Currently Executive Director - Novartis
• Smithkline Beecham/GSK(1999-2001 USA Group Director)
• Smithkline Beecham Director (1992-2001 Munich)
• Developing and implementing Clinical Programme EU/US/Japan
• Developing and implementing marketing strategy for several brands
• Major launch of several products and indications in US/EU
• Outlicencing and in-licensing expertise
• Regulatory expertise in EU/US/Japan

Scientific Advisory Board

Chair:

Prof. Dwight Evans (University of Philadelphia) General Psychiatry

Members:

Prof. Sigfried Kaspar (University of Vienna) General Psychiatry

Prof. David Nutt (University of Bristol) Psychopharmacology

Prof. Les Iversen (University of London) Psychopharmacology

Prof. Tamas Bartfai (Scripp Institute) Psychopharmacology

Prof. Ken Davis (Mount Sinai Hospital) Schizophrenia/Dementia